Physicians

Departments / Divisions

• Medicine / Medicine - Cardiology
• Community and Family Medicine / NORTHERN PIEDMONT COMMUNITY CARE

Address
DUMC 2708
Durham, NC 27710

2424 Erwin Road, Suite 403
Durham, NC 27705

Appointment Telephone
919-681-5816

Office Telephone
919-668-8796

Fax Telephone
919-668-7097

Training

• MD, Johns Hopkins University School of Medicine (Maryland), 1978-1982

Residency

• Medicine, Barnes Hospital (Washington), 1982-1985

Fellowship

• Cardiology, Duke University Medical Center, 1986-1988

Clinical Interests
Coronary artery disease, percutaneous coronary intervention (angioplasty), stent implantation, laser angioplasty, chronic total coronary occlusion, antiplatelet therapy, anticoagulation therapy, clinical trials, computers in medicine, databases, medical informatics, quality and outcomes

Research Interests
In addition to my clinical responsibilities as an interventional cardiologist, my research interests include the study of antithrombotic therapies in cardiovascular disease and biomedical informatics and information technologies.

My research is applied (clinical research), primarily focusing on the evaluation of technologies in the clinical arena.

I have participated in numerous clinical trials and have also conducted several multicenter studies, including the EPIC, PROLOG, EPILOG, EPISTENT, IMPACT, IMPACT II, TOTAL, PRIDE, ESPRIT, MEND-1, and ELECT Trials.

My areas of expertise are an outgrowth of my clinical research, and includes use of the new antiplatelet therapeutics in the treatment of coronary artery disease; treatment of unstable angina and acute myocardial infarction; quality assurance and quality improvement; application of informatics and information technology to the delivery of care; and the application of excimer laser coronary angioplasty in the treatment of coronary artery disease.

Key words: angioplasty, excimer laser, platelet glycoproteins, computers, clinical trials.

Industry Relationships and Collaborations (What's this?)

This faculty member (or a member of their immediate family) has a working relationship (i.e. consulting, research, and/or educational services) with the companies listed below. These relations have been reported to the health system leadership and, when appropriate, management plans are in place to address potential conflicts.

• American Board of Internal Medicine
• American College of Cardiology Foundation
• Cardiovascular Systems, Inc.
• Faculty Connection
• Ischemix, Inc.
• Philips Medical Systems

Representative Publications
Deibele, AJ; Jennings, LK; Tcheng, JE; Neva, C; Earhart, AD; Gibson, CM. Intracoronary eptifibatide bolus administration during percutaneous coronary revascularization for acute coronary syndromes with evaluation of platelet glycoprotein IIb/IIIa receptor occupancy and platelet function: the Intracoronary Eptifibatide (ICE) Trial. Circulation. 2010;121:784-791. (2010) Abstract

Guerra, DR; Tcheng, JE. Prasugrel: Clinical development and therapeutic application. Advances in Therapy. 2009;26:999-1011. (2009) Abstract

Tcheng, JE; Lim, IH; Srinivasan, S; Jozic, J; Gibson, CM; O'Shea, JC; Puma, JA; Simon, DI. Stent parameters predict major adverse clinical events and the response to platelet glycoprotein IIb/IIIa blockade: findings of the ESPRIT trial. Circulation: Cardiovascular Interventions. 2009;2:43-51. (2009) Abstract

Tcheng, JE; Zidar, DA. Gone but not forgotten: the case for drug-eluting stents in percutaneous revascularization of the chronic coronary total occlusion. JACC: Cardiovascular Interventions. 2009;2:1266-1268. (2009) Abstract

Casterella, PJ; Tcheng, JE. Review of the 2005 American College of Cardiology, American Heart Association, and Society for Cardiovascular Interventions guidelines for adjunctive pharmacologic therapy during percutaneous coronary interventions: practical implications, new clinical data, and recommended guideline revisions. American Heart Journal. 2008;155:781-790. (2008) Abstract

Denardo, SJ; Davis, KE; Tcheng, JE. Effectiveness and safety of reduced-dose enoxaparin in non-ST-segment elevation acute coronary syndrome followed by antiplatelet therapy alone for percutaneous coronary intervention. American Journal of Cardiology. 2007;100:1376-1382. (2007) Abstract

Dery, JP; Campbell, ME; Mathias, J; Pieper, KS; Harrington, RA; Madan, M; Gibson, CM; Tolleson, TR; O'Shea, JC; Tcheng, JE; ESPRIT Investigators. Complementary effects of thienopyridine pretreatment and platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention; results from the ESPRIT trial. Catheterization and Cardiovascular Interventions. 2007;70:43-50. (2007) Abstract

Musser, RC; Tcheng, JE. Quantitative and qualitative comparison of text-based and graphical user interfaces for Computerized Provider Order Entry. 2006;1041. (2006) Abstract

Puma, JA; Banko, LT; Pieper, KS; Sacchi, TJ; O'Shea, JC; Dery, JP; Tcheng, JE. Clinical characteristics predict benefits from eptifibatide therapy during coronary stenting: insights from the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy (ESPRIT) trial. Journal of the American College of Cardiology. 2006;47:715-718. (2006) Abstract

Tcheng, JE. Debate of adjunctive pharmacology for percutaneous coronary intervention: anticoagulation and clopidogrel are not (always) enough. Journal of Interventional Cardiology: an international forum for global cardiovascular therapies. 2006;19:456-463. (2006) Abstract

Tcheng, JE; Kinney, KG. After fibrinolysis: is cardiac catheterization the answer?. Journal of the American College of Cardiology. 2006;48:1336-1338. (2006) Abstract